Miruvor
Sign up
The short answer

What studies of binders (cholestyramine, clays) found

1paper on binders (cholestyramine, clays)
1 (few people)person in 1 study testing binders (cholestyramine, clays) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 3 findings, all C.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Binders (cholestyramine, clays) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Binders (cholestyramine, clays) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue1 study · 1 (few people) person tried binders (cholestyramine, clays) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months (few people)

Fatigue improved.

The evidence is very uncertain about the effect of binders (cholestyramine, clays) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature. (2026)

    People in the study
    1 in the study
    Dose
    3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months
    Outcome
    fatigue
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person tried binders (cholestyramine, clays) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of binders (cholestyramine, clays) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature. (2026)

    People in the study
    1 in the study
    Dose
    3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months
    Outcome
    Bell CFIDS disability scale
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person tried binders (cholestyramine, clays) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · at five different time points (IP Test 1–5) · 3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of binders (cholestyramine, clays) on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature. (2026)

    People in the study
    1 in the study
    Dose
    3 × 900 mg capsules (total 8.1 g/day), three times a day ... for 4 months
    Outcome
    reduction in symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Fatigue1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    900 mg at the start

  2. 2Top dose

    Most often 900 mg (1 of 1 studies)

Doses across 1 study

900 to 900 mg.

Each study’s dose, as printed

All papers

  1. Intestinal permeability correlated with chronic fatigue in a patient with long COVID-A case report and overview of the literature.2026 · case report · 1 in the study
    Summary

    This single case report describes a 60-year-old female with long COVID who was examined at a gastroenterology outpatient clinic with chronic fatigue and autonomic dysfunction. There was no comparison group. Intestinal permeability was assessed with a carbohydrate absorption test at five different time points (IP Test 1–5), alongside fatigue and the Bell CFIDS disability scale. The patient received Innovall FD™ (Bacillus coagulans and Bacillus subtilis), one capsule containing 2.5 × 109 CFU twice daily for 3 months. During that time, her fatigue continued to subside, and the patient reported a reduction in symptoms, corresponding to an increase of around 20 on the Bell CFIDS disability scale from initial baseline of 40–60. Later, after symptoms and fatigue increased again (Bell CFIDS disability scale 40), she received medicinal clay (Luvos-Heilerde imutox™), 3 × 900 mg capsules (total 8.1 g/day) three times a day for 4 months. Within 6 months following the initiation of medicinal clay therapy, the patient experienced a remission of symptoms (Bell CFIDS disability scale 100), and in clinical follow-ups she remained in remission. The medicinal clay was discontinued to prevent potential malabsorption of nutrients associated with medicinal clay. The authors state that this is a single case report and generalizations cannot be made.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime